Cite
HARVARD Citation
Socinski, M. et al. (2021). Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. Therapeutic advances in medical oncology. p. . [Online].